Use the filters below to narrow your search.
Filter results
You can narrow down the results using the filters.
Topics
- Shortages and supply disruptions (22)
- Safety monitoring and information (13)
- Manufacturing (7)
- Compliance and enforcement (6)
- Labelling and packaging (4)
- Import and export (3)
- Scheduling (national classification system) (3)
- Committees and advisory bodies (2)
- Legislation (2)
- Advertising (1)
- Clinical trials (1)
- Fees and payments (1)
- Medicinal cannabis hub (1)
Collection content
114 result(s) found, displaying 31 to 40
-
GuidanceGuidance about the types of notifications and variations for chemically derived (non-biological) prescription medicines.
-
GuidanceGuidance on the mandatory requirements for reporting current and anticipated reportable medicine shortages and discontinuations in Australia.
-
GuidanceGuidance about application pathways and data requirements for new generic medicines, and variations to existing medicines.
-
GuidanceGuidance to understand the quality requirements of Therapeutic Goods Order No. 101 - Standard for tablets, capsules and pills (TGO 101, the Order).
-
GuidanceGuidance for sponsors about how to apply for orphan drug designation for a prescription medicine.
-
GuidanceGuidance on submitting the CPD for prescription medicines.
-
GuidanceGuidance on specific criteria and paperwork required for submission to the TGA to ensure conformance with TGO 93.
-
GuidanceGuidance on how to prepare your application for orphan drug designation so that it meets eligibility criteria and requirements.
-
PageEvaluation plan estimators to approximate dates of milestones in the prescription medicine registration process.
-
GuidanceGuidance on applying for a provisional determination, which is the first step of the provisional approval pathway.